Select your Market
Financial results for Q2 2025
Forecast 2025
| Q2 2025 (in € billion) | Change (in %, compared to Q2 2024) | Organic change (in %, compared to Q2 2024) |
|---|---|---|---|
Group net sales | 5.3 | –1.8 | 2.0 |
EBITDA pre | 1.5 | –3.1 | 4.6 |
Life Science sales | 2.3 | 0.4 | 3.7 |
Healthcare sales | 2.1 | –1.6 | 3.6 |
Electronics sales | 0.9 | –7.4 | –5.6 |
We have delivered solid underlying sales and earnings growth. By standing on three pillars – Life Science, Healthcare and Electronics – we are, as a Group, better able to withstand the geopolitical, economic and currency swings that are buffeting companies around the world.
Our CEO Belén Garijo comments on the Q2 2025 results.
Detailed information about the development of our business in the first half of 2025.
Downloads for the Media
Press Releases
Strong sales in Process Solutions and for blockbusters Mavenclad and Erbitux, sustained demand for Semiconductor Materials.
2025/08/07
Our Q3 2025 results will be published on November 13, 2025, at 7 a.m. (CET). Our conference call for the media will take place at 09:30 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Our Q4 2025 results will be published on March 5, 2026, at 7 a.m. (CET). Our press conference will take place at 10:00 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Media Relations
Head of Investor Relations
+49 6151 72 91-5271
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
